Paper Details

  1. Home
  2. Paper Details

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma.

Author: CohenRoger B, GunnarssonOrvar, KeefeStephen M, PfanzelterNicklas R

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Axitinib, a tyrosine kinase inhibitor, is effective in treating advanced kidney cancer (second-line treatment). It improves progression-free survival by 6.7 months compared to 4.7 months with sorafenib. Common side effects include hypertension (16%), diarrhea (11%), and fatigue (11%). Higher diastolic blood pressure (>90 mmHg) is linked to better survival outcomes.
Paper Details　
Original Abstract of the Article :
Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor-α, and c-kit. Phase I studies demonstrated 5 mg twice daily as the recommended starting dose with notable effects seen in renal cell carcinoma, an observation confirmed in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334173/

データ提供：米国国立医学図書館（NLM）

Axitinib: A Promising Treatment for Advanced Renal Cell Carcinoma

This research evaluates the safety and efficacy of axitinib, a tyrosine kinase inhibitor, in treating advanced renal cell carcinoma (RCC). RCC is a type of kidney cancer that can be challenging to treat, and axitinib has emerged as a promising second-line therapy option. The study highlights the effectiveness of axitinib in prolonging progression-free survival, demonstrating its significant potential for improving patient outcomes.

A New Hope for Advanced RCC

The study provides compelling evidence for the effectiveness of axitinib in treating advanced RCC. The researchers found that axitinib significantly extended progression-free survival compared to sorafenib, offering a potential breakthrough in the management of this challenging disease.

Navigating Treatment Options for RCC

The study emphasizes the importance of exploring various treatment options for advanced RCC, highlighting the role of axitinib as a valuable second-line therapy. The research encourages patients to discuss their treatment options with their healthcare providers to determine the most appropriate course of action based on their individual circumstances.

Dr.Camel's Conclusion

This study, like a camel caravan finding a vital water source in the desert, provides hope for patients with advanced RCC. The research demonstrates the efficacy of axitinib in prolonging progression-free survival, offering a valuable tool for managing this challenging disease. The study emphasizes the importance of exploring various treatment options and collaborating with healthcare providers to determine the most suitable approach for each patient.

Date :
  1. Date Completed 2015-02-24
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

25709499

DOI: Digital Object Identifier

PMC4334173

Related Literature

Article Analysis
・Side Effects of axitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.